TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16703336
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of enamel matrix derivative and bioactive glass (group 2, n=13)
Study: 12658483
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (GH) 0.3 IU/kg/day subcutaneously from day 3 before operation until day 7 after operation
Study: 12658483
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (GH)
Study: 12658483
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (GH) and Placebo
Study: 10955339
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (LLLT) for RA
Study: 10955339
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (LLLT) for OA
Study: 1431344
Drug: Anti-CEA monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-CEA monoclonal antibody (F023C5) radioimmunoscintigraphy (RIS)
Study: 3855601
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 in 1 mg dose
Study: 3855601
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 in 2 mg dose
Study: 3855601
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 in 3 mg dose
Study: 3855601
Drug: Placebo (vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vaginal triacetin gel)
Study: 22045925
Drug: Telemonitoring (TM)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Telemonitoring (TM) for 6 months, measuring body weight, blood pressure, and heart rate daily with electronic devices.
Study: 20101186
Drug: Valproate (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valproate (20 mg/kg/day)
Study: 20101186
Drug: Lithium (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (800 mg/day)
Study: 18037769
Drug: Pycnogenol (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pycnogenol (180 mg/day)
Study: 10392392
Drug: 1450 T
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1450 T lead (steroid group)
Study: 1824736
Drug: mannitol (15‐g
Approvals — FDA: no, EMA: no, PMDA: no
Description: mannitol (15‐g bolus followed by 15% infusion mixed in 75 mmol/L saline at 100 mL/h for 1 hour)
Study: 1824736
Drug: saline (equal
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline (equal volume of 75 mmol/L saline, intravenously)
Study: 31345387
Drug: reduced-dose chemoradiation
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: reduced-dose chemoradiation (rdCRT) with 5600 cGy and weekly carboplatin
Study: 31345387
Drug: standard-dose chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard-dose chemoradiotherapy (sdCRT) with 7000 cGy
Study: 27707550
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ranibizumab (RBZ)
Study: 27707550
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg ranibizumab (RBZ)
Study: 21914410
Drug: Intrathecal immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal immunoglobulin in addition to standard treatment (group A)
Study: 21914410
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment only (group B)
Study: 16842145
Drug: New pharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: New pharmacological approaches to improve vascular homeostasis, specifically targeting oxidative stress reduction or antioxidant defense augmentation.
Study: 15160263
Drug: Perospirone 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perospirone 4 mg
Study: 15160263
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg plus perospirone 4 mg
Study: 9369917
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy for chemo-sensitive tumors
Study: 9369917
Drug: Instillation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instillation of drugs like doxycycline, OK-432, or bleomycin
Study: 3512070
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy plus immunotherapy with Nocardia rubra cell-wall skeleton (N-CWS) and irradiated allogeneic AML cells
Study: 30524633
Drug: Combination Therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Therapy (CT) with lumbopelvic stability training (LPST)
Study: 30524633
Drug: Standard Massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Massage Therapy (MT)
Study: 28324268
Drug: Ridaforolimus 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ridaforolimus 30 mg daily for 5 of 7 days plus dalotuzumab 10 mg/kg/week
Study: 28324268
Drug: Any ridaforolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any ridaforolimus dose
Study: 28324268
Drug: Ridaforolimus 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ridaforolimus 20 mg qd x 5 days/week
Study: 28324268
Drug: Ridaforolimus 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ridaforolimus 10 mg qd x 5 days/week
Study: 20462580
Drug: Weekly telephone
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly telephone support
Study: 16299259
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen (HBO(2)) over 20 treatments
Study: 15270890
Drug: Topical paricalcitol
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical paricalcitol ointment (15 microg g(‐1))
Study: 12067146
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBO2T)
Study: 9359979
Drug: moclobemide (MOC;
Approvals — FDA: no, EMA: no, PMDA: no
Description: moclobemide (MOC; 400 mg daily)
Study: 9359979
Drug: nortriptyline (NT;
Approvals — FDA: no, EMA: no, PMDA: no
Description: nortriptyline (NT; 75 mg daily)
Study: 3535008
Drug: Ketanserin, 40‐160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin, 40‐160 mg daily
Study: 31106659
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid group: 2 omega-3 fatty acid capsules (330 mg each) daily + vitamin D3 placebo weekly
Study: 31106659
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D group: 50,000 IU vitamin D3 soft gel weekly + 2 omega-3 fatty acid placebo capsules daily
Study: 31106659
Drug: Cosupplementation group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cosupplementation group: 50,000 IU vitamin D3 soft gel weekly + 2 omega-3 fatty acids capsules daily for 8 weeks
Study: 31106659
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: vitamin D3 placebo weekly + omega-3 fatty acid placebo capsules daily
Study: 27751554
Drug: MIS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIS plus alteplase (0.3 mg or 1.0 mg every 8 hours for up to nine doses)
Study: 20374035
Drug: Rhodiola algida
Normalized name: RHODIOLA ROSEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhodiola algida mixture consumed for 14 consecutive days after each cycle of chemotherapy
Study: 18389895
Drug: Comparator ritonavir‐boosted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator ritonavir‐boosted protease inhibitor (CPI/r)
Study: 16288157
Drug: Exercise program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise program (45-50 minutes, twice a week for 8 weeks)
Study: 11414432
Drug: Artesunate 200
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate 200 mg once daily for 3 days
Study: 11414432
Drug: Artesunate 200
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate 200 mg together with mefloquine 10 mg/kg on the first 2 days and artesunate 200 mg together with mefloquine 5 mg/kg on the third day
Study: 11414432
Drug: Artesunate 200
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate 200 mg together with azithromycin 50 mg once daily for 3 days
Study: 8439637
Drug: Early nizatidine
Normalized name: Nizatidine
DrugBank: Nizatidine (DB00585)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early nizatidine (300 mg) with early supper (18.00 hours)
Study: 8439637
Drug: Late nizatidine
Normalized name: Nizatidine
DrugBank: Nizatidine (DB00585)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late nizatidine (300 mg) with late supper (21.00 hours)
Study: 8439637
Drug: Early nizatidine
Normalized name: Nizatidine
DrugBank: Nizatidine (DB00585)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early nizatidine (300 mg) with late supper (21.00 hours)
Study: 29143803
Drug: High-protein diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein diet (125 g protein/day) using novel functional foods
Study: 29143803
Drug: Conventional diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional diet (80 g protein/day)
Study: 16412769
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist plus recombinant luteinizing hormone
Study: 16412769
Drug: Standard GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard GnRH agonist flare-up protocol
Study: 11417474
Drug: Daunorubicin continuous
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin continuous infusion (CI) 60 mg/m2 days 2-4
Study: 11417474
Drug: Bolus daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bolus daunorubicin (30-min infusion) 60 mg/m2
Study: 11417474
Drug: Daunorubicin continuous
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin continuous infusion (CI)
Study: 11417474
Drug: Bolus daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bolus daunorubicin (30-min infusion)
Study: 9562303
Drug: Anti-NF antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-NF antibodies in ALS patients
Study: 8179465
Drug: Desipramine (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (long-term treatment for 28 days)
Study: 8179465
Drug: Desipramine (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (long-term treatment)
Study: 3068741
Drug: Nifedipine, 10
Normalized name: Nifedipine, 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine, 10 mg three times a day
Study: 21803405
Drug: 80 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 μg delprostenate
Study: 21803405
Drug: 160 μg
Normalized name: immunoglobulin G, human 160 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 μg delprostenate
Study: 16513871
Drug: Risperidone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (2.5 mg)
Study: 9307345
Drug: Sertraline hydrochloride
Normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline hydrochloride (50-150 mg daily)
Study: 334132
Drug: Acetazolamide 63
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide 63 mg
Study: 24028643
Drug: Acetazolamide 125
Normalized name: acetazolamide 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 125 mg
Study: 1544778
Drug: Acetazolamide 500
Normalized name: acetazolamide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 500 mg
Study: 334132
Drug: Acetazolamide 0
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide 0 mg (control)
Study: 27417302
Drug: Education and
Normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education and acceptance and commitment therapy intervention (n=39)
Study: 18251162
Drug: Vitamin K2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K2 (VK2), 45 mg orally every day after therapy for HCC
Study: 18251162
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no VK2 treatment)
Study: 15771794
Drug: Paraplatin dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paraplatin dosage calculated according to body surface
Study: 15771794
Drug: Paraplatin dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paraplatin dosage calculated according to area under the curve (AUC)
Study: 9883316
Drug: LPS stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS stimulation (5 micrograms/ml)
Study: 9883316
Drug: NDV stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: NDV stimulation (640 HU/ml)
Study: 2048708
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (tourniquet applied after midazolam injection)
Study: 2048708
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I (tourniquet applied before midazolam injection)
Study: 7044525
Drug: Tamoxifen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (10 mg p.o. twice daily)
Study: 7044525
Drug: Aminoglutethimide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglutethimide (250 mg p.o. 4 times daily) with hydrocortisone (20 mg twice daily)
Study: 25394826
Drug: Inhaled oxygen
Normalized name: oxygen Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled oxygen fraction (FiO₂) 1.0, 0.21, 0.15, and 0.10 with body positions (upright, supine, and 45° head down)
Study: 21490143
Drug: ZnSuppl group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZnSuppl group (6 mg Zn added to the supplement dose)
Study: 21490143
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (30 g dry weight of iron-fortified cereal porridge and a liquid multivitamin supplement without zinc)
Study: 21490143
Drug: ZnFort group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZnFort group (zinc added to provide 6 mg Zn per 25 g dry weight of porridge and multivitamin without zinc)
Study: 19622294
Drug: Celecoxib plus
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib plus surgery (200 mg twice daily for six days before surgery)
Study: 6373303
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy for non-responders
Study: 23253701
Drug: Standard-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-intensity warfarin (INR 2.1 to 2.5)
Study: 23253701
Drug: Low-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity warfarin (INR 1.6 to 2.0)
Study: 23253701
Drug: Aspirin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (200 mg per day)
Study: 23253701
Drug: Standard-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-intensity warfarin
Study: 10369553
Drug: Zemaphyte (traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zemaphyte (traditional Chinese herbal medicine)
Study: 2669155
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 50 mg/day
Study: 1930859
Drug: Nifedipine (NIF)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine (NIF) 90 mg/day
Study: 3911962
Drug: Suprofen suppositories
Normalized name: Suprofen
DrugBank: Suprofen (DB00870)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suprofen suppositories
Study: 24397109
Drug: Granulocyte-colony stimulating
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Granulocyte-colony stimulating factor (GCSF); dosage and duration not specified.
Study: 16804018
Drug: Fermented papaya
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented papaya preparation 9 g/day
Study: 12654667
Drug: 1263W94 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1263W94 (50 to 1,600 mg)
Study: 12654667
Drug: 1263W94 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1263W94 (100 to 1,600 mg)
Study: 8634929
Drug: Heater probe
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heater probe thermocoagulation therapy and cimetidine 300mg i.v. q6h
Study: 8634929
Drug: Omeprazole 40mg
Normalized name: OMEPRAZOLE 40MG CAP,SA
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 40mg intravenous bolus initially followed by 40mg i.v. qd
Study: 8634929
Drug: Omeprazole 40mg
Normalized name: OMEPRAZOLE 40MG CAP,SA
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 40mg intravenous bolus initially followed by 40mg i.v. q12h
Study: 1473431
Drug: Piroxicam-beta-cyclodextrin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam-beta-cyclodextrin (20 mg/day for 14 days)
Study: 1473431
Drug: Standard Piroxicam
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Piroxicam (20 mg/day for 14 days)
Study: 1473431
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg/day for 14 days)
Study: 24995756
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement pharmacotherapy (6-week regimen)
Study: 24995756
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no nicotine replacement therapy)
Study: 20141732
Drug: Integrated traditional
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated traditional Chinese medicine therapy and chemotherapy
Study: 17394179
Drug: anti-tumor necrosis
Normalized name: G 1 (anti-tumor agent)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-tumor necrosis factor alpha (anti-TNFalpha) therapy
Study: 15826418
Drug: Autologous blood
Normalized name: Banked autologous blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous blood re-infusion units
Study: 7784683
Drug: Continuous intrathecal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intrathecal anesthesia with 10 mg hyperbaric bupivacaine (Group 1)
Study: 7784683
Drug: Continuous intrathecal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intrathecal anesthesia with 10 mg hyperbaric bupivacaine and 25 mcg fentanyl (Group 2)
Study: 7784683
Drug: Single intrathecal
Normalized name: Intrathecal Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intrathecal dose of 15 mg hyperbaric bupivacaine (Group 3)
Study: 2113756
Drug: Selegiline (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline (30 mg/day)
Study: 474476
Drug: 11.5 mg
Normalized name: pectin 11.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11.5 mg zinc daily
Study: 474476
Drug: 14.7 mg
Normalized name: arginine 14.7 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14.7 mg zinc daily
Study: 31041683
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy alone (ET)
Study: 31041683
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus endocrine therapy (ET + C)
Study: 23359344
Drug: Tabalumab 30
Normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tabalumab 30 mg
Study: 23359344
Drug: Tabalumab 60
Normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tabalumab 60 mg
Study: 23359344
Drug: Tabalumab 160
Normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tabalumab 160 mg
Study: 23359344
Drug: Tabalumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tabalumab (all doses combined)
Study: 20888709
Drug: RT +
Normalized name: CVS Yogurt + Fiber Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT + cisplatin (20 mg/m² weekly)
Study: 16551158
Drug: Youth‐Nominated Support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Youth‐Nominated Support Team‐Version 1 (YST‐1) plus treatment-as-usual
Study: 16551158
Drug: Treatment-as-usual only
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual only
Study: 8006643
Drug: Interferon-alpha (IFN)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha (IFN) therapy
Study: 9106647
Drug: Oral etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral etoposide (100 mg given twice daily for 5 days)
Study: 9106647
Drug: Intravenous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chemotherapy (cisplatin and etoposide alternating with cyclophosphamide, doxorubicin, and vincristine)
Study: 8459986
Drug: Ondansetron plus
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron plus dexamethasone (0.15 mg/kg i.v. x 3 and 20 mg i.v.)